Merck to Shut Down London-Based Drug Research Facility
Merck (MRK.N) announced on Wednesday that it will be closing its research operations in London, citing the challenging business environment in the UK.
The company confirmed that it no longer plans to operate out of Belgrove House in King’s Cross, a facility that was scheduled to open in 2027. The closure will affect approximately 125 employees.
Merck stated that it will transfer its research activities to existing sites, primarily in the United States.
With tariff threats from the Trump administration and increasing pressure to shift more manufacturing to the U.S., pharmaceutical companies are ramping up investment in American operations.
In its statement, Merck said, “This decision reflects the challenges posed by the UK’s underinvestment in the life sciences sector and the lack of meaningful progress by successive British governments in addressing the broader devaluation of innovative medicines and vaccines.”
Continuing the achievement of the journey of effectiveness and credibility of more than 10 years in the career of journalism, as a woman journalist, I am Serving as the founder, promoter and editor of DiaryTimes with the trust and support of all. My credible coverage may not have given a big shape to the numbers, but my journey presents articles that make you aware of the exact and meaningful situations of Himachal’s politics, ground issues related to the public, business, tourism and the difficult geographical conditions of the state and financial awareness. DiaryTimes, full of the experience of my precise editorial expertise, is awakening the flame of credible journalism among all of you, so that the eternal flame of meaningful change can be lit in the life of the people of the state and the atrocities being committed against the people can be brought to the fore, I am motivated for that. If even a small change comes with the power of my journalism and the whole world becomes a witness to that issues, then I will consider myself fortunate.
